HTR1B and coronary artery disorder: Due to vasoconstriction associated with the 5-hydroxytryptamine receptor 1B (5-HT1B) activity, triptans are contraindicated in patients with ischemic coronary artery disease (CAD), coronary artery vasospasm, Wolff-Parkinson-White syndrome, peripheral vascular disease, ischemic bowel disease, and uncontrolled hypertension and in patients with a history of cerebrovascular ischemic events [19–25].